share_log

Cerevel Therapeutics Hldg Analyst Ratings

Cerevel Therapeutics Hldg Analyst Ratings

Cerevel Therapeutics 控股分析師評級
Benzinga ·  2023/09/28 17:23
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating
09/28/2023 56.77% Piper Sandler → $33 Initiates Coverage On → Overweight
08/07/2023 18.76% Mizuho $29 → $25 Maintains Neutral
08/03/2023 99.52% Morgan Stanley $46 → $42 Maintains Overweight
08/03/2023 47.27% B of A Securities $36 → $31 Downgrades Buy → Neutral
08/03/2023 94.77% HC Wainwright & Co. $45 → $41 Maintains Buy
05/23/2023 42.52% Goldman Sachs $31 → $30 Maintains Neutral
05/08/2023 37.77% Mizuho $26 → $29 Maintains Neutral
05/04/2023 42.52% Wells Fargo → $30 Upgrades Equal-Weight → Overweight
04/10/2023 — TD Cowen Initiates Coverage On → Outperform
04/03/2023 113.78% HC Wainwright & Co. → $45 Reiterates → Buy
03/17/2023 37.77% JP Morgan $40 → $29 Downgrades Overweight → Neutral
03/16/2023 4.51% Berenberg → $22 Reinstates → Hold
03/09/2023 23.52% Mizuho $28 → $26 Maintains Neutral
02/23/2023 90.02% Morgan Stanley $50 → $40 Maintains Overweight
02/23/2023 113.78% HC Wainwright & Co. $48 → $45 Maintains Buy
02/23/2023 42.52% Wells Fargo $38 → $30 Downgrades Overweight → Equal-Weight
02/22/2023 47.27% Goldman Sachs $28 → $31 Maintains Neutral
12/06/2022 90.02% JP Morgan $49 → $40 Maintains Overweight
11/10/2022 33.02% Mizuho $32 → $28 Maintains Neutral
11/09/2022 128.03% HC Wainwright & Co. $50 → $48 Maintains Buy
11/01/2022 90.02% Loop Capital → $40 Initiates Coverage On → Buy
10/20/2022 85.27% B of A Securities → $39 Initiates Coverage On → Buy
09/29/2022 94.77% Cantor Fitzgerald → $41 Initiates Coverage On → Overweight
09/26/2022 80.52% Wells Fargo → $38 Initiates Coverage On → Overweight
09/21/2022 33.02% Goldman Sachs $24 → $28 Maintains Neutral
09/13/2022 — Evercore ISI Group Initiates Coverage On → Outperform
08/23/2022 52.02% Mizuho $27 → $32 Maintains Neutral
08/22/2022 137.53% Morgan Stanley $39 → $50 Maintains Overweight
08/09/2022 156.53% Stifel $50 → $54 Maintains Buy
08/03/2022 28.27% Mizuho $30 → $27 Maintains Neutral
07/07/2022 42.52% Mizuho → $30 Initiates Coverage On → Neutral
05/24/2022 -4.99% Goldman Sachs $28 → $20 Maintains Neutral
02/15/2022 28.27% Goldman Sachs → $27 Initiates Coverage On → Neutral
01/05/2022 137.53% JP Morgan → $50 Initiates Coverage On → Overweight
12/16/2021 137.53% HC Wainwright & Co. → $50 Initiates Coverage On → Buy
09/07/2021 85.27% Morgan Stanley $27 → $39 Maintains Overweight
06/18/2021 28.27% Morgan Stanley → $27 Initiates Coverage On → Overweight
12/10/2020 14.01% Goldman Sachs → $24 Initiates Coverage On → Buy
11/23/2020 -14.49% Jefferies → $18 Initiates Coverage On → Buy
11/09/2020 -19.24% Stifel → $17 Initiates Coverage On → Buy
日期 上行/下行 分析公司 目標價格變化 評級變化 上一次/當前評級
09/28/2023 56.77% 派珀·桑德勒 →$33 開始承保 →超重
08/07/2023 18.76% 瑞穗 $29→$25 維護 中性
08/03/2023 99.52% 摩根士丹利 $46→$42 維護 超重
08/03/2023 47.27% B of A證券 $36→$31 評級下調 購買→中性
08/03/2023 94.77% HC Wainwright公司 $45→$41 維護 買
2023年05月23日 42.52% 高盛 $31→$30 維護 中性
05/08/2023 37.77% 瑞穗 $26→$29 維護 中性
05/04/2023 42.52% 富國銀行 →$30 升級 等重→超重
04/10/2023 - TD Cowen 開始承保 →跑贏大盤
04/03/2023 113.78% HC Wainwright公司 →$45 重申 →購買
03/17/2023 37.77% 摩根大通 $40→$29 評級下調 超重→中性
03/16/2023 4.51% 貝倫伯格 →$22 恢復 →保留
03/09/2023 23.52% 瑞穗 $28→$26 維護 中性
02/23/2023 90.02% 摩根士丹利 $50→$40 維護 超重
02/23/2023 113.78% HC Wainwright公司 $48→$45 維護 買
02/23/2023 42.52% 富國銀行 $38→$30 評級下調 超重→等重
02/22/2023 47.27% 高盛 $28→$31 維護 中性
12/06/2022 90.02% 摩根大通 $49→$40 維護 超重
2022年11月10日 33.02% 瑞穗 $32→$28 維護 中性
11/09/2022 128.03% HC Wainwright公司 $50→$48 維護 買
11/01/2022 90.02% 環路資本 →$40 開始承保 →購買
10/20/2022 85.27% B of A證券 →$39 開始承保 →購買
09/29/2022 94.77% 康託·菲茨傑拉德 →$41 開始承保 →超重
09/26/2022 80.52% 富國銀行 →$38 開始承保 →超重
2022/09/21 33.02% 高盛 $24→$28 維護 中性
09/13/2022 - Evercore ISI集團 開始承保 →跑贏大盤
2022年08月23日 52.02% 瑞穗 $27→$32 維護 中性
2022/08/22 137.53% 摩根士丹利 $39→$50 維護 超重
08/09/2022 156.53% Stifel $50→$54 維護 買
08/03/2022 28.27% 瑞穗 $30→$27 維護 中性
07/07/2022 42.52% 瑞穗 →$30 開始承保 →中性
2022年05月24日 -4.99% 高盛 $28→$20 維護 中性
02/15/2022 28.27% 高盛 →$27 開始承保 →中性
01/05/2022 137.53% 摩根大通 →$50 開始承保 →超重
12/16/2021 137.53% HC Wainwright公司 →$50 開始承保 →購買
09/07/2021 85.27% 摩根士丹利 $27→$39 維護 超重
06/18/2021 28.27% 摩根士丹利 →$27 開始承保 →超重
12/10/2020 14.01% 高盛 →$24 開始承保 →購買
11/23/2020 -14.49% 傑富瑞 →$18 開始承保 →購買
11/09/2020 -19.24% Stifel →$17 開始承保 →購買

What is the target price for Cerevel Therapeutics Hldg (CERE)?

Cerevel Treateutics Hldg(CERE)的目標價格是多少？

There is no price target for Cerevel Therapeutics Hldg

Cerevel Treeutics Hldg沒有價格目標

What is the most recent analyst rating for Cerevel Therapeutics Hldg (CERE)?

Cerevel Treateutics Hldg(CERE)最近的分析師評級是什麼？

There is no analyst for Cerevel Therapeutics Hldg

Cerevel Treateutics Hldg沒有分析師

When is the next analyst rating going to be posted or updated for Cerevel Therapeutics Hldg (CERE)?

Cerevel Treateutics Hldg(CERE)的下一次分析師評級將於何時發佈或更新？

There is no next analyst rating for Cerevel Therapeutics Hldg

Cerevel Treateutics Hldg沒有下一個分析師評級

Is the Analyst Rating Cerevel Therapeutics Hldg (CERE) correct?

分析師對Cerevel Treateutics Hldg(CERE)的評級正確嗎？

There is no next analyst rating for Cerevel Therapeutics Hldg

Cerevel Treateutics Hldg沒有下一個分析師評級

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論